Oslo Sports Trauma Research Center, Department of Sports Medicine, Norwegian School of Sport Sciences, PO Box 4014 Ullevaal Stadion, 0806 Oslo, Norway.
Am J Sports Med. 2012 Mar;40(3):542-7. doi: 10.1177/0363546511433012. Epub 2012 Jan 11.
A randomized controlled study has shown promising clinical results after treatment with sclerosing injections in a group of patients with patellar tendinopathy, but no study has investigated medium- or long-term outcome in a large and unselected group of patients.
To investigate if sclerosing treatment would affect the level of patellar tendon pain and knee function after 24 months in a large group of patients with patellar tendinopathy.
Case series; Level of evidence, 4.
This prospective study recruited patients with a clinical diagnosis of jumper's knee and visible neovascularization corresponding to the painful area on power Doppler ultrasound. They received up to a maximum of 5 ultrasound-guided sclerosing injections using polidocanol at 4- to 6-week intervals. Knee pain and function were recorded using the Victorian Institute of Sport Assessment-Patella (VISA-P) score before treatment and 6, 12, and 24 months after the first injection.
In total, 101 patients (15 women and 86 men) with 120 tendons were included and given from 1 to 5 sclerosing injections (mean [SD], 2.5 [0.9]). The patients reported a significantly improved VISA-P score from baseline (mean, 39; 95% confidence interval [CI], 36-42) to the 24-month follow-up (mean, 65; 95% CI, 60-70) (range, 21-100; P < .001, paired t test). However, a VISA-P score of >95 points was reported in only 22 cases (20%), whereas 37 cases (36%) reported a VISA-P score of <50 at 24 months.
Sclerosing treatment with polidocanol resulted in a moderate improvement in knee function and reduced pain in a heterogeneous group of patients with patellar tendinopathy. Nevertheless, few of the patients were cured, and the majority still had reduced function and substantial pain after 24 months of follow-up.
一项随机对照研究表明，在一组髌腱病患者中进行硬化注射治疗具有有前景的临床结果，但尚无研究在大量未经选择的患者群体中调查中期或长期结果。
调查在髌腱病患者的大群体中，硬化治疗是否会在 24 个月后影响髌腱疼痛和膝关节功能的水平。
病例系列；证据水平，4。
这项前瞻性研究招募了临床诊断为跳跃膝且在功率多普勒超声上与疼痛区域相对应的可见新生血管的患者。他们在 4-6 周的间隔内接受了最多 5 次超声引导下的聚多卡醇硬化注射。在第一次注射前、注射后 6 个月、12 个月和 24 个月，使用维多利亚运动评估-髌腱（VISA-P）评分记录膝关节疼痛和功能。
共纳入 101 例患者（15 名女性和 86 名男性）的 120 个肌腱，并接受了 1 至 5 次硬化注射（平均[标准差]，2.5[0.9]）。患者报告 VISA-P 评分从基线（平均 39；95%置信区间 [CI]，36-42）显著改善到 24 个月随访（平均 65；95%CI，60-70）（范围，21-100；P<.001，配对 t 检验）。然而，只有 22 例（20%）报告 VISA-P 评分>95 分，而 37 例（36%）在 24 个月时报告 VISA-P 评分<50 分。
用聚多卡醇进行硬化治疗可使髌腱病患者群体的膝关节功能得到适度改善，并减轻疼痛。然而，少数患者痊愈，大多数患者在 24 个月的随访后仍存在功能下降和明显疼痛。
